Epic Sciences

DermTech Appoints Mark Aguillard as Chief Commercial Officer

Retrieved on: 
Monday, September 11, 2023

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023.
  • Mr. Aguillard will lead DermTech’s overall commercial strategy and execution.
  • Commenting on Mr. Aguillard’s appointment, Bret Christensen, DermTech’s CEO said, “I’d like to welcome Mark to the team.
  • Mr. Aguillard received his Bachelor’s in Business Administration with a major in Finance from Texas Tech University.

Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments

Retrieved on: 
Monday, April 24, 2023

These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si's growing customer base and further scaling of the company.

Key Points: 
  • These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si's growing customer base and further scaling of the company.
  • Prior to this, Ms. Atkinson held executive leadership positions at Truvian, Epic Sciences, Edico Genome and Illumina.
  • Mr. Hutcheson has more than 20 years of experience as a commercial professional within the genomics, biotechnology, and drug discovery markets.
  • Its elegant simplicity enables broad-scale access to proteomic data, making it a critical instrument for the future of proteomics research.

Epic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBC

Retrieved on: 
Friday, April 14, 2023

Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months.

Key Points: 
  • Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months.
  • We have delivered comprehensive test results to 700 patients and their oncologists in our Clinical Experience Program,” said Lloyd Sanders, President and CEO, Epic Sciences.
  • The investment also continues to fund the development of additional concordance and outcomes data for the DefineMBC tests.
  • Andrew El Bardissi, a member of the company’s board of directors and Partner at Deerfield Management, said, “Deerfield is pleased to support Epic Sciences at this critical stage of commercialization.

EPIC SCIENCES EXPANDS EXECUTIVE TEAM AND WELCOMES NEW CHIEF FINANCIAL OFFICER IN PREPARATION FOR RAPID GROWTH

Retrieved on: 
Tuesday, November 1, 2022

SAN DIEGO, Nov. 1, 2022 /PRNewswire/ -- Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnostics company, announces the appointment of William J. Kullback as Chief Financial Officer (CFO), while previous CFO, Joel S. Smith, will continue in his other executive roles as General Counsel, Chief Compliance Officer, and Executive Vice President of Corporate Development.

Key Points: 
  • SAN DIEGO, Nov. 1, 2022 /PRNewswire/ -- Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnostics company, announces the appointment of William J. Kullback as Chief Financial Officer (CFO), while previous CFO, Joel S. Smith, will continue in his other executive roles as General Counsel, Chief Compliance Officer, and Executive Vice President of Corporate Development.
  • As we plan to scale the organization, I am especially pleased to announce an expansion of our executive team in a manner that ensures continuity of leadership and positions Epic for substantial growth.
  • Joel will continue to lead Epic's legal, licensing and compliance affairs and will ensure a seamless transition as Bill assumes the CFO role.
  • "On behalf of the entire Epic team, I welcome Bill and look forward to his contributions."

EPIC SCIENCES' DefineMBC™ TEST DELIVERS COMPREHENSIVE LIQUID BIOPSY RESULTS FOR METASTATIC BREAST CANCER

Retrieved on: 
Wednesday, May 4, 2022

SAN DIEGO, May 4, 2022 /PRNewswire/ -- Epic Sciences, Inc. has added DefineMBC™, a novel comprehensive blood-based test for characterizing metastatic breast cancer, to its CLIA laboratory menu.

Key Points: 
  • 20 US Clinical Cancer Centers, 16 Metastatic Breast Cancer Trials now powered by Epic Sciences platform
    SAN DIEGO, May 4, 2022 /PRNewswire/ -- Epic Sciences, Inc. has added DefineMBC, a novel comprehensive blood-based test for characterizing metastatic breast cancer, to its CLIA laboratory menu.
  • DefineMBC includes both cell-based and cell-free analysis from a single blood draw to provide comprehensive profiling of metastatic breast cancer when a tissue biopsy result is not available.
  • "We have also benefitted tremendously from the input and ongoing collaboration with multiple leading breast cancer oncologists throughout development.
  • The Company's liquid biopsy platform leverages proven, proprietary cell analysis capabilities as well as cell-free analysis to provide more complete, efficient analysis and clearer insights Comprehensive Cancer Profiling.

EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE PARTNERSHIP FOR METASTATIC CANCER TRIALS

Retrieved on: 
Thursday, January 27, 2022

As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials.

Key Points: 
  • As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials.
  • "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre, MD, PhD, Chief Medical Officer, Oncology at Biosplice Therapeutics.
  • "This Biosplice collaboration highlights our ability to provide deep insights into discovery findings and clinical trials results," says Lloyd Sanders, CEO and President at Epic Sciences.
  • Epic Sciences, Inc. is developing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancer.

EPIC SCIENCES UNVEILS DefineMBC™, A NOVEL BLOOD-BASED TEST DESIGNED TO IMPROVE CARE FOR METASTATIC BREAST CANCER PATIENTS

Retrieved on: 
Thursday, December 16, 2021

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ --Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw.

Key Points: 
  • SAN DIEGO, Dec. 16, 2021 /PRNewswire/ --Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw.
  • DefineMBC uses both cell-based and cell-free analysis from a simple blood draw and provides information for optimal treatment decision making," says Rick Wenstrup MD, Chief Medical Officer, Epic Sciences.
  • Epic Sciences, Inc. is developing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancer.
  • Using its full-service CLIA/CAP accredited laboratory and research support services in San Diego, Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.

EPIC sciences platform Demonstrates compelling Value of Cell Analysis in data Presented AT San Antonio Breast Cancer Symposium 2021

Retrieved on: 
Wednesday, December 8, 2021

SAN DIEGO, Dec. 8, 2021 /PRNewswire/ --Epic Sciences, Inc. (Epic)'s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.

Key Points: 
  • SAN DIEGO, Dec. 8, 2021 /PRNewswire/ --Epic Sciences, Inc. (Epic)'s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.
  • Since 2018, the Epic platform has been providing clinically validated predictive information about selective hormone therapy resistance for patients with metastatic prostate cancer.
  • Epic Sciences, Inc. is developing novel diagnostics to guide therapy selection and monitor disease progression, personalizing and advancing the treatment and management of prostate and breast cancer.
  • Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.

Epic Sciences Expands Leadership Team to Address Liquid Biopsy Demand

Retrieved on: 
Wednesday, November 3, 2021

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Epic Sciences, Inc, developer of novel diagnostics to personalize and advance the treatment and management of cancer, today announced the appointment of Jason Christiansen as Chief Technology Officer, Mark Aguillard as Vice President/ General Manager of the Oncology Business Unit, and Amara Siva as Vice President of Laboratory Operations. These three new executives bring a combined 60 plus years of delivery experience to the Epic Sciences team.

Key Points: 
  • These three new executives bring a combined 60 plus years of delivery experience to the Epic Sciences team.
  • "I am honored to join Epic Sciences' team," she says.
  • "Joining the Epic Sciences' team to promote commercial growth of cancer testing was an easy decision," says Aguillard.
  • Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.

Akoya Biosciences Appoints Pascal Bamford, PhD, as SVP, R&D and Laboratory Operations

Retrieved on: 
Tuesday, October 26, 2021

MARLBOROUGH, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (Akoya), The Spatial Biology Company, today announced the appointment of Pascal Bamford, PhD, as Senior Vice President, Research and Development and Laboratory Operations.

Key Points: 
  • MARLBOROUGH, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (Akoya), The Spatial Biology Company, today announced the appointment of Pascal Bamford, PhD, as Senior Vice President, Research and Development and Laboratory Operations.
  • His experience includes developing commercial Research-Use Only (RUO) tools, In Vitro Diagnostics (IVD), and clinical Laboratory Developed Tests (LDTs).
  • We are delighted to welcome Pascal to the leadership team of Akoya Biosciences, said Brian McKelligon, CEO of Akoya Biosciences.
  • Akoya is a leader in the field and is uniquely positioned to enable and accelerate those outcomes.